StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research note issued to investors on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Up 1.5%
Shares of NASDAQ LPCN opened at $3.28 on Friday. Lipocine has a twelve month low of $2.75 and a twelve month high of $11.79. The stock’s 50 day moving average price is $3.24 and its 200-day moving average price is $4.13. The company has a market capitalization of $17.55 million, a PE ratio of -4.32 and a beta of 1.52.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.35 million.
Institutional Investors Weigh In On Lipocine
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- What Are Treasury Bonds?
- Constellation Powers Up With Reinforced AI Data Center Strategy
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Top Analyst-Rated Healthcare Stocks to Watch Now
- 3 Small Caps With Big Return Potential
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.